Northbrook, Illinois Clinical Trials

A listing of Northbrook, Illinois clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 396 clinical trials
featured
Food for Thought.

This study is looking for people with mild to moderate Alzheimer’s. The study is testing the effects of eating a study food product.

Great Lakes Clinical Trials - Arlington Heights
 (7.0 away) Contact site
  • 0 views
  • 15 Sep, 2020
  • +1 other locations
featured
Art Therapy Research Study.

This study is looking for people who have early stage Alzheimer’s. The study is testing the effects of art therapy on relationships.

Advocate Memory Center
 (8.0 away) Contact site
  • 0 views
  • 23 Nov, 2020
  • 1 location
featured
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations.  

cancer
FGFR2
primary tumor
solid tumors
solid tumor
Illinois Cancer Specialists
 (8.3 away) Contact site
  • 46 views
  • 14 Dec, 2020
  • +61 other locations
featured
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

This is an open-label, randomized (1:1), multicenter, Phase 3 clinical trial evaluating the safety and efficacy of nivolumab in combination with investigational agent sitravatinib compared to docetaxel in patients with advanced non-squamous NSCLC who have previously experienced radiographic disease progression on or after treatment with platinum-based chemotherapy in combination with …

cancer
experimental drug
lung carcinoma
lung cancer
cancer chemotherapy
Illinois Cancer Specialists - Niles
 (6.7 away) Contact site
  • 199 views
  • 24 May, 2021
  • +174 other locations
featured
Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET

Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET

Mirati Research Site
 (9.2 away) Contact site
  • 342 views
  • 08 Nov, 2020
  • +37 other locations
featured
A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

Deerbrook Medical Associates
 (9.6 away) Contact site
  • 2362 views
  • 23 Nov, 2020
  • +17 other locations
featured
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.

lung metastases
recurrent non-small cell lung cancer
advanced lung cancer
refractory non-small cell lung cancer
metastatic non-small cell lung cancer
Mirati Research Site
 (8.3 away) Contact site
  • 0 views
  • 08 Jun, 2021
  • +33 other locations
featured
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation

Evaluates the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and clinical activity of MRTX849 in patients with advanced solid tumors with a KRAS G12C mutation. MRTX849 is an orally-available small molecule inhibitor of KRAS G12C.

malignant solid tumor
solid tumor
advanced solid tumor
Mirati Research Site
 (6.7 away) Contact site
  • 405 views
  • 08 Mar, 2021
  • +66 other locations
featured
Arise 2 - A Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia

This is a randomized, placebo-controlled, double-blind, crossover study of oral BTD-001 in adults with Idiopathic Hypersomnia.  

hypersomnia
Fort Wayne Neurology
 (152.5 away) Contact site
  • 607 views
  • 23 Nov, 2020
  • +17 other locations
featured
Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-7)

This Phase 2 study evaluates the clinical activity and safety of MRTX849 in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS.

KRAS
pembrolizumab
USOR - Illinois Cancer Specialists - Niles
 (6.7 away) Contact site
  • 0 views
  • 10 Jun, 2021
  • +32 other locations